# Pharmlinc

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmlinc

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.genessential.com
- Total disclosed funding: $1.4M
- Latest round: Angel (Dec 27, 2018)
- Investors on record: 1

## About

Pharmlinc is a company engaged in construction decoration engineering, providing architectural design and specialized contracting services for building renovation projects, utilizing advanced technologies to enhance product efficacy.Founded in 2017, Pharmlinc focuses on the construction decoration engineering sector, offering services that include architectural design and specialized contracting. The company is headquartered in Beijing, China. In December 2018, Pharmlinc secured CNY 10 million in Angel funding from Beijing Amphora Venture Capital, bringing its total funds raised to CNY 10 million, with a current valuation of CNY 100 million.Pharmlinc operates in the construction decoration engineering sector, offering services that encompass architectural design and specialized contracting for renovation projects. The company utilizes advanced technologies such as ultra-deep cooling with liquid nitrogen or argon to enhance the physical and chemical properties of its offerings, which include reinforced construction equipment and machinery. Its clientele spans infrastructure development, commercial establishments, and industrial operations, delivering high-quality solutions tailored to diverse construction needs, primarily targeting urban markets in Asia while selectively expanding into international territories.Pharmlinc generates revenue through structured B2B and direct-to-consumer transactions, engaging in contractual agreements with clients on a project basis. Fees are determined based on project requirements and scale, with additional income from the sale of specialized equipment, including flagship products designed for construction and engineering applications. Clients primarily consist of construction firms and commercial developers, with financial dealings structured around agreed deliverables and milestones throughout project lifecycles.Pharmlinc plans to utilize the recent Angel funding of CNY 10 million raised in December 2018 to support the development of new products and expand into new markets. Specific geographic regions targeted for expansion include urban areas across Asia and select international territories, with plans to launch new offerings aligned with market demands. The strategic use of this funding will aid in enhancing product innovations and facilitating the company’s growth initiatives.

## Funding rounds

- Angel, Dec 27, 2018, $1.4M — Amphora Capital

## Investors

- Amphora Capital (https://capitalatlas.ai/funds/amphora-capital) — Angel